Immix Biopharma, Inc. (IMMX) announced that it has priced a $150 million underwritten registered offering of its common stock.
Offering details
The offering includes 16,778,524 shares of its common stock priced at $8.94 per share, generating expected gross proceeds of $150 million before underwriting discounts and expenses.
The transaction is expected to close on or about May 22, 2026, subject to customary closing conditions.
Morgan Stanley is serving as the lead book-running manager, with BofA Securities acting as book-running manager. LifeSci Capital, Mizuho and Needham & Company are participating as co-lead managers.
Use of Proceeds
Immix said it intends to use the net proceeds to support development of its lead CAR-T therapy NXC-201, along with working capital and general corporate purposes. The company expects that the new capital, combined with existing cash, will fund operations into mid-2028.
Pipeline Snapshot: NXC-201
Immix's lead candidate is a sterically optimized BCMA-targeted CAR-T therapy designed with a "digital filter" to reduce non-specific immune activation. The therapy aims to train the immune system to eliminate toxic light chains that drive AL amyloidosis, a life-threatening disease that can cause heart, kidney, and liver failure.
NXC-201 is currently being evaluated in NEXICART-2 U.S. multicenter study for relapsed/refractory AL amyloidosis, which features a potentially registrational design.
The program has received multiple regulatory designations, including Breakthrough Therapy Designation, RMAT and Orphan Drug status from the FDA, and Orphan Drug Designation from the EMA.
IMMX has traded between $1.87 and $11.61 over the past year. The stock closed Thursday's trading at $8.94, up 0.90%. In pre-market trading the stock is at $9.70, up 8.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.